Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Rachel B Jones; Shunsuke Furuta; Jan Willem Cohen Tervaert; Thomas Hauser; Raashid Luqmani; Matthew D Morgan; Chen Au Peh; Caroline O Savage; Mårten Segelmark; Vladimir Tesar; Pieter van Paassen; Michael Walsh; Kerstin Westman; David Rw Jayne

doi:10.1136/annrheumdis-2014-206404

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Rachel B Jones, Shunsuke Furuta, Jan Willem Cohen Tervaert, Thomas Hauser, Raashid Luqmani, Matthew D Morgan, Chen Au Peh, Caroline O Savage, Mårten Segelmark, Vladimir Tesar, Pieter van Paassen, Michael Walsh, Kerstin Westman, David Rw Jayne

Nephrology

Research output: Contribution to journal › Article › peer-review

Abstract

The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.

Original language	English
Pages (from-to)	1178-1182
Journal	Annals of the Rheumatic Diseases
Volume	74
Issue number	6
DOIs	https://doi.org/10.1136/annrheumdis-2014-206404
Publication status	Published - 2015

Subject classification (UKÄ)

Clinical Medicine

Access to Document

10.1136/annrheumdis-2014-206404

http://www.ncbi.nlm.nih.gov/pubmed/25739829?dopt=Abstract

Cite this

Jones, R. B., Furuta, S., Cohen Tervaert, J. W., Hauser, T., Luqmani, R., Morgan, M. D., Peh, C. A., Savage, C. O., Segelmark, M., Tesar, V., van Paassen, P., Walsh, M., Westman, K., & Jayne, D. R. (2015). Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Annals of the Rheumatic Diseases, 74(6), 1178-1182. https://doi.org/10.1136/annrheumdis-2014-206404

@article{9e097ce3c38b4eaf934f05394a1e12df,

title = "Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.",

abstract = "The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.",

author = "Jones, {Rachel B} and Shunsuke Furuta and {Cohen Tervaert}, {Jan Willem} and Thomas Hauser and Raashid Luqmani and Morgan, {Matthew D} and Peh, {Chen Au} and Savage, {Caroline O} and M{\aa}rten Segelmark and Vladimir Tesar and {van Paassen}, Pieter and Michael Walsh and Kerstin Westman and Jayne, {David Rw}",

year = "2015",

doi = "10.1136/annrheumdis-2014-206404",

language = "English",

volume = "74",

pages = "1178--1182",

journal = "Annals of the Rheumatic Diseases",

issn = "1468-2060",

publisher = "BMJ Publishing Group",

number = "6",

}

Jones, RB, Furuta, S, Cohen Tervaert, JW, Hauser, T, Luqmani, R, Morgan, MD, Peh, CA, Savage, CO, Segelmark, M, Tesar, V, van Paassen, P, Walsh, M, Westman, K & Jayne, DR 2015, 'Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.', Annals of the Rheumatic Diseases, vol. 74, no. 6, pp. 1178-1182. https://doi.org/10.1136/annrheumdis-2014-206404

TY - JOUR

T1 - Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

AU - Jones, Rachel B

AU - Furuta, Shunsuke

AU - Cohen Tervaert, Jan Willem

AU - Hauser, Thomas

AU - Luqmani, Raashid

AU - Morgan, Matthew D

AU - Peh, Chen Au

AU - Savage, Caroline O

AU - Segelmark, Mårten

AU - Tesar, Vladimir

AU - van Paassen, Pieter

AU - Walsh, Michael

AU - Westman, Kerstin

AU - Jayne, David Rw

PY - 2015

Y1 - 2015

N2 - The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.

AB - The RITUXVAS trial reported similar remission induction rates and safety between rituximab and cyclophosphamide based regimens for antineutrophil cytoplasm antibody (ANCA)-associated vasculitis at 12 months; however, immunosuppression maintenance requirements and longer-term outcomes after rituximab in ANCA-associated renal vasculitis are unknown.

U2 - 10.1136/annrheumdis-2014-206404

DO - 10.1136/annrheumdis-2014-206404

M3 - Article

C2 - 25739829

SN - 1468-2060

VL - 74

SP - 1178

EP - 1182

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 6

ER -

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial.

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this